CVS Health Corporation (FRA:CVS)
Germany · Delayed Price · Currency is EUR | Market Cap | 106.90B +48.5% |
| Revenue (ttm) | 351.79B +7.7% |
| Net Income | 2.54B -44.5% |
| EPS | 1.99 -45.2% |
| Shares Out | n/a |
| PE Ratio | 42.04 |
| Forward PE | 12.80 |
| Dividend | 2.28 (2.76%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | n/a |
| Average Volume | 82 |
| Open | 83.56 |
| Previous Close | 82.54 |
| Day's Range | 83.56 - 83.56 |
| 52-Week Range | 50.27 - 83.56 |
| Beta | n/a |
| RSI | 79.23 |
| Earnings Date | Aug 5, 2026 |
About CVS Health
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individu... [Read more]
Financial Performance
In 2025, CVS Health's revenue was $399.83 billion, an increase of 7.87% compared to the previous year's $370.66 billion. Earnings were $1.77 billion, a decrease of -61.68%.
Financial numbers in USD Financial StatementsNews
CVS unit Omnicare wins court approval for sale to GenieRx
Omnicare, a unit of health insurer CVS Health , said on Wednesday a U.S. bankruptcy court has approved the sale of its business to GenieRx Holdings.
CVS Health granted court approval for sale of business to GenieRx
CVS Health (CVS) subsidiary Omnicare announced that following a comprehensive sale process, the U.S. Bankruptcy Court for the Northern District of Texas has approved the sale of the company’s business...
Omnicare Receives Court Approval for Sale of Business to GenieRx
WOONSOCKET, R.I., May 13, 2026 /PRNewswire/ -- Omnicare, LLC (the "Company" or "Omnicare"), a subsidiary of CVS Health (NYSE: CVS), today announced that following a comprehensive sale process, the U.S...
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
MinuteClinic highlights access and outcomes in clinically supervised weight-loss program
In-person and virtual services support chronic disease prevention and long-term metabolic health WOONSOCKET, R.I., May 13, 2026 /PRNewswire/ -- As chronic conditions tied to metabolic health continue ...
CVS Health price target raised to $106 from $94 at Bernstein
Bernstein raised the firm’s price target on CVS Health (CVS) to $106 from $94 and keeps an Outperform rating on the shares. The firm continues to see CVS as having…
CVS Health price target raised to $111 from $101 at JPMorgan
JPMorgan raised the firm’s price target on CVS Health (CVS) to $111 from $101 and keeps an Overweight rating on the shares.
CVS Health price target raised to $110 from $105 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on CVS Health (CVS) to $110 from $105 and keeps a Buy rating on the shares. The firm said they…
Health Insurers Performing Better But There's Potential Trouble Ahead
Health insurance companies including UnitedHealthcare, CVS Health's Aetna, Centene and Blue Cross and Blue Shield plans owned by Elevance Health are seeing lower costs from patients submitting claims.
CVS Health price target raised to $103 from $102 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on CVS Health (CVS) to $103 from $102 and keeps an Overweight rating on the shares. The firm is constructive…
CVS Health price target raised to $92 from $88 at Deutsche Bank
Deutsche Bank raised the firm’s price target on CVS Health (CVS) to $92 from $88 and keeps a Buy rating on the shares.
CVS Health price target raised to $107 from $90 at RBC Capital
RBC Capital raised the firm’s price target on CVS Health (CVS) to $107 from $90 and keeps an Outperform rating on the shares. The company reported a strong Q1 beat…
CVS Health price target raised to $105 from $100 at Evercore ISI
Evercore ISI raised the firm’s price target on CVS Health (CVS) to $105 from $100 and keeps an Outperform rating on the shares.
CVS Health price target raised to $102 from $98 at Truist
Truist raised the firm’s price target on CVS Health (CVS) to $102 from $98 and keeps a Buy rating on the shares. The company reported strong Q1 results while its…
CVS Health price target raised to $101 from $93 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on CVS Health (CVS) to $101 from $93 and keeps an Overweight rating on the shares post the Q1 report. CVS…
CVS Health price target raised to $100 from $95 at BofA
BofA raised the firm’s price target on CVS Health (CVS) to $100 from $95 and keeps a Buy rating on the shares after the company reported a Q1 beat with…
CVS Health price target raised to $100 from $97 at UBS
UBS raised the firm’s price target on CVS Health (CVS) to $100 from $97 and keeps a Buy rating on the shares. CVS delivered a strong Q1 beat with improved…
CVS Health reports Q1 adjusted EPS $2.57, consensus $2.21
Reports Q1 revenue $100.43B, consensus $95.02B. The company said, “CVS Health (CVS) continues to provide what people want most from health care: a connected, convenient, cost-effective engagement expe...
CVS Health raises FY26 adjusted EPS view to $7.30-$7.50 from $7.00-$7.20
Consensus $7.16. Raises FY26 cash flow from operations view to at least $9.5B from at least $9B. The company said, “The Company is increasing its full-year 2026 GAAP diluted EPS,…
CVS Health raises FY26 revenue view to ‘at least’ $405B from ‘at least’ $400B
FY26 revenue consensus $404.95B. Raises FY26 adjusted operating income view to $15.53B-$15.87B from $15.07B-$15.41B. Guidance taken from investor presentation slides.
CVS Health says ‘encouraged’ by Q1 performance
Says final 2027 rates for Medicare Advantage plans remain insufficient to offset underlying medical cost trends. Comments taken from Q1 earnings conference call.
CVS Health says confident in adequacy of reserves
Says ended Q1 with 3.84x leverage ratio and expects to drive further improvement by year-end. Sees 60/40 split of earnings between 1H26 and 2H26, respectively.
CVS Health Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and earnings growth, with adjusted EPS up 14% and full-year guidance raised. Segment performance was robust, especially in Health Care Benefits and value-based care, while investments in technology and regulatory adaptation remain key priorities.
CVS Profits Eclipse $2.9 Billion As Aetna Health Plan Costs Ease
CVS Health Wednesday reported first quarter net income of more than $2.9 billion as costs slowed for subscribers of the Aetna health plans the company sells.
CVS Health raises 2026 forecast after improving medical cost controls
CVS Health raised its full-year forecast on Wednesday, aided by increased first-quarter earnings in the company's pharmacy management business and strong medical cost controls in its government-spons...